Literature DB >> 23024835

ACS chemical neuroscience molecule spotlight on Suvorexant.

Corey R Hopkins1.   

Abstract

Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23024835      PMCID： PMC3447389          DOI： 10.1021/cn300086a

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  4 in total

1.  Insomnia and the performance of US workers: results from the America insomnia survey.

Authors:  Ronald C Kessler; Patricia A Berglund; Catherine Coulouvrat; Goeran Hajak; Thomas Roth; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

Review 2.  Prevalence, associated risks, and treatment patterns of insomnia.

Authors:  Thomas Roth
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

3.  Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

Authors:  Christopher D Cox; Michael J Breslin; David B Whitman; John D Schreier; Georgia B McGaughey; Michael J Bogusky; Anthony J Roecker; Swati P Mercer; Rodney A Bednar; Wei Lemaire; Joseph G Bruno; Duane R Reiss; C Meacham Harrell; Kathy L Murphy; Susan L Garson; Scott M Doran; Thomayant Prueksaritanont; Wayne B Anderson; Cuyue Tang; Shane Roller; Tamara D Cabalu; Donghui Cui; George D Hartman; Steven D Young; Ken S Koblan; Christopher J Winrow; John J Renger; Paul J Coleman
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

4.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205
  4 in total
  1 in total

1.  Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice.

Authors:  Keishi Etori; Yuki C Saito; Natsuko Tsujino; Takeshi Sakurai
Journal:  Front Neurosci       Date:  2014-01-31       Impact factor: 4.677
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.